Case report: SAF-189s is a potent inhibitor in a lorlatinib-resistant NSCLC patient with acquired compound mutations ALK L1196M and D1203N
Article in Frontiers in Pharmacology (December 2023)
The most recent citing publications are shown below. View all 3 publications that cite this research output on Dimensions.
Article in Frontiers in Pharmacology (December 2023)
Article in Translational Lung Cancer Research (September 2023)
Article in Journal of Drug Targeting (June 2022)